Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Genus tumbles after warning on full-year profits

(Sharecast News) - Genus shares tumbled on Thursday as the animal genetics company warned on full-year profits. In a first-half trading update, the company said it had performed "resiliently" in challenging market conditions. It expects to report revenue of £334m and adjusted pre-tax profit of £29m, in line with expectations.

The group said that excluding China, PIC - its global porcine genetics business - performed "robustly", with North America, Latin America and Europe delivering adjusted operating profit growth in constant currency.

Genus said China continues to be a challenging porcine market, but that its "enhanced commercial focus" has resulted in winning new royalty customers in the period which will have a positive impact in fiscal year 2025 and beyond.

The company said its bovine genetics business, ABS, saw volumes fall 6% in challenging markets. There was a particular hit to demand for dairy genetics in China due to a double-digit decline in the dairy herd.

Genus said that assuming present market conditions persist for the balance of the fiscal year, fiscal year 2024 adjusted pre-tax profit is set to be "not less than" £58m in actual currency. This is down from £71.5m a year earlier.

Deutsche Numis said this compares with its current forecast of £72.8m

As far as its PRRS Resistant Pig (PRP) programme is concerned, Genus said recent engagement with the US Food and Drug Administration has shifted to the post-approval compliance procedures.

"This has clarified the data submissions and monitoring that will be required on an ongoing basis post PRP approval.

"Validation of our procedures to comply with these monitoring requirements is expected to take several months. We therefore now expect FDA approval in fiscal year 2025."

At 0905 GMT, the shares were down 27% at 1,555.84p.

Share this article

Related Sharecast Articles

JPMorgan Chase Q1 profits jump
(Sharecast News) - JPMorgan Chase reported a 6% jump in first-quarter profit on Friday as net interest income rose.
R&Q Insurance shares plummet on weak guidance
(Sharecast News) - R&Q Insurance, the AIM-listed non-life insurer, lost almost half of its market value on Friday after announcing it would report a "significant pre-tax loss" for last year.
SigmaRoc delivers 'solid' Q1 performance
(Sharecast News) - Limestone group SigmaRoc said on Friday that it had delivered a "solid Q1 performance", with underlying earnings in line with management expectations.
Samsung in line to secure $6bn in US government grants
(Sharecast News) - Electronics giant Samsung will unveil a $44.0bn White House programme aimed at bringing semiconductor production back to America as soon as next week, with the memory chip maker in line to secure up to $6.0bn in government grants.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.